Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHPL-49 in acute ischemic stroke
NCT06202378Phase 2Completed
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SHPL-49 in ischemic stroke (3 arms). Primary endpoint: Modified Rankin Scale with scores of 0-1 at 90 days. Started Dec 2023; status: completed.
02
Drugs
SHPL-49
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06202378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202378.